electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 12, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 12, 2025, after market close. The company will host a webcast and conference call at 5:30 PM EDT where management will discuss the financial results and conduct a Q&A session.
Details
News Market Reaction – ECOR
The recorded move for ECOR in the trading session of this news was -5.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025.
Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions.
Conference Call & Webcast Details
Date: Wednesday, March 12, 2025
Time: 5:30 PM EDT
Registration: Click here to register to receive login credentials and dial-in details.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (nVNS) technology platform. The company focuses on commercializing medical devices for managing and treating specific medical conditions, as well as consumer products utilizing nVNS to enhance general well-being and human performance in the United States and select international markets.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
Investors@electrocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.